NextGen cell and gene therapy has been saved
Analysis
NextGen cell and gene therapy
Personalized precision medicine is here
Cell and gene therapy (CGT) brings the promise of personalized precision medicine to life. As with any innovative, disruptive technology, however, developers face challenges along several dimensions—manufacturing, regulation, and reimbursement, among them—to become broadly commercially viable. How can life sciences organizations address these challenges and continue to advance CGTs?
Deloitte’s CGT experience spans the value chain
Our goal is to bring the best of Deloitte to help our cell and gene therapy manufacturing clients launch curative therapies that will benefit patients and humankind. Our capabilities and experience span the entire CGT value chain, from clinical operations and research and development (R&D) to technology and digital platforms to supply chain, logistics, and manufacturing.
Discover insights
Why elevating responsibility to the c-suite can help avoid manufacturing missteps
Designing a patient-centric digital ecosystem
Your operating model needs to be as innovative as your science
${column4-title}
${column4-text}
NextGen Therapies Industry Working Group
Orchestrating cell and gene therapies to better manage patient treatment journeys
Life Sciences Home
${column4-title}
${column4-text}
Get in touch
 |
Hussain Mooraj |
 |
Amit Agarwal |
 |
Omkar Kawalekar |
|||||
 |
Jennifer Rabin |
 |
Jessica Faust |
Recommendations
The supply chain DNA question for life sciences companies
What analysis may reveal about potential tax risks in an era of tax reform
Automating quality assurance in pharmaceutical, biotechnology, and medical devices
Racing to keep up with robotic process automation in life sciences
